Cancers, Vol. 16, Pages 1462: The Challenge for a Correct Diagnosis of Refractory Thrombocytopenia: ITP or MDS with Isolated Thrombocytopenia?
nidis
Immune thrombocytopenia (ITP) is an autoimmune disease characterized by isolated thrombocytopenia. It is diagnosed in patients with a platelet count below 100,000 per cubic millimeter in whom other causes of thrombocytopenia have been ruled out, and its diagnosis is generally one of exclusion. Clinical manifestations of patients may vary from asymptomatic disease to mild mucocutaneous or life-threatening bleeding. Glucocorticoids are used as first-line treatment for ITP, while other second-line medications, mainly thrombopoietin-receptor agonists (TPO-RA) and rituximab, are given to patients in whom ITP does not ...
Source: Cancers - April 11, 2024 Category: Cancer & Oncology Authors: Aikaterini Kosmidou Eleni Gavriilaki Athanasios Tragiannidis Tags: Review Source Type: research
Anti-aquaporin-4 immunoglobulin G/anti-myelin oligodendrocyte glycoprotein immunoglobulin G double-positive paraneoplastic neurological syndrome in a patient with triple-negative breast cancer
We report a rare case of paraneoplastic neurological syndrome with dual seropositivity of anti-aquaporin-4 and myelin oligodendrocyte glycoprotein antibodies in a 40 year-old woman with metastatic triple-negative breast cancer. She received multiple lines of anti-neoplastic treatment, including immunotherapy with pembrolizumab, as well as cytotoxic chemotherapy. Paraneoplastic meningoencephalomyelitis developed 2 years after diagnosis of breast cancer and 1 year after discontinuation of immunotherapy with pembrolizumab. She first developed longitudinally extending transverse myelitis followed by left optic neuritis and men...
Source: Clinical Breast Cancer - April 10, 2024 Category: Cancer & Oncology Authors: Amna Siddiqui Dylan Ross Ronak H Jani Vikram C Prabhu Shelly Lo Derek A Wainwright Stasia Rouse Tamer Refaat Yirong Zhu Jigisha P Thakkar Source Type: research
Anti-aquaporin-4 immunoglobulin G/anti-myelin oligodendrocyte glycoprotein immunoglobulin G double-positive paraneoplastic neurological syndrome in a patient with triple-negative breast cancer
We report a rare case of paraneoplastic neurological syndrome with dual seropositivity of anti-aquaporin-4 and myelin oligodendrocyte glycoprotein antibodies in a 40 year-old woman with metastatic triple-negative breast cancer. She received multiple lines of anti-neoplastic treatment, including immunotherapy with pembrolizumab, as well as cytotoxic chemotherapy. Paraneoplastic meningoencephalomyelitis developed 2 years after diagnosis of breast cancer and 1 year after discontinuation of immunotherapy with pembrolizumab. She first developed longitudinally extending transverse myelitis followed by left optic neuritis and men...
Source: Clinical Genitourinary Cancer - April 10, 2024 Category: Cancer & Oncology Authors: Amna Siddiqui Dylan Ross Ronak H Jani Vikram C Prabhu Shelly Lo Derek A Wainwright Stasia Rouse Tamer Refaat Yirong Zhu Jigisha P Thakkar Source Type: research
A phase 2, open-label study of ibrutinib plus rituximab in Japanese patients with Waldenstrom's macroglobulinemia
This study evaluated the efficacy and safety of ibrutinib-rituximab in Japanese patients with WM. Patients received ibrutinib 420 mg orally once daily plus weekly rituximab 375 mg/m2 IV (8 infusions total). The primary end point was major response rate (MRR; PR or better) by Independent Review Committee assessment. Secondary endpoints were progression-free survival (PFS), safety, pharmacokinetics, and biomarkers. Primary analysis was conducted in 16 patients [baseline, treatment naïve: 8 (50.0%); relapsed/refractory WM: 8 (50.0%)] who received ibrutinib-rituximab, after all patients completed Week 57 or end of treatment. ...
Source: International Journal of Hematology - April 10, 2024 Category: Hematology Authors: Koji Izutsu Hisashi Kato Naohiro Sekiguchi Tomoaki Fujisaki Toshiro Kawakita Naoshi Obara Kosei Matsue Mitsutaka Nishimoto Tomoyoshi Hatayama Mitsuo Inagaki Ei Fujikawa Source Type: research
Anti-aquaporin-4 immunoglobulin G/anti-myelin oligodendrocyte glycoprotein immunoglobulin G double-positive paraneoplastic neurological syndrome in a patient with triple-negative breast cancer
We report a rare case of paraneoplastic neurological syndrome with dual seropositivity of anti-aquaporin-4 and myelin oligodendrocyte glycoprotein antibodies in a 40 year-old woman with metastatic triple-negative breast cancer. She received multiple lines of anti-neoplastic treatment, including immunotherapy with pembrolizumab, as well as cytotoxic chemotherapy. Paraneoplastic meningoencephalomyelitis developed 2 years after diagnosis of breast cancer and 1 year after discontinuation of immunotherapy with pembrolizumab. She first developed longitudinally extending transverse myelitis followed by left optic neuritis and men...
Source: Clinical Breast Cancer - April 10, 2024 Category: Cancer & Oncology Authors: Amna Siddiqui Dylan Ross Ronak H Jani Vikram C Prabhu Shelly Lo Derek A Wainwright Stasia Rouse Tamer Refaat Yirong Zhu Jigisha P Thakkar Source Type: research
Anti-aquaporin-4 immunoglobulin G/anti-myelin oligodendrocyte glycoprotein immunoglobulin G double-positive paraneoplastic neurological syndrome in a patient with triple-negative breast cancer
We report a rare case of paraneoplastic neurological syndrome with dual seropositivity of anti-aquaporin-4 and myelin oligodendrocyte glycoprotein antibodies in a 40 year-old woman with metastatic triple-negative breast cancer. She received multiple lines of anti-neoplastic treatment, including immunotherapy with pembrolizumab, as well as cytotoxic chemotherapy. Paraneoplastic meningoencephalomyelitis developed 2 years after diagnosis of breast cancer and 1 year after discontinuation of immunotherapy with pembrolizumab. She first developed longitudinally extending transverse myelitis followed by left optic neuritis and men...
Source: Clinical Genitourinary Cancer - April 10, 2024 Category: Cancer & Oncology Authors: Amna Siddiqui Dylan Ross Ronak H Jani Vikram C Prabhu Shelly Lo Derek A Wainwright Stasia Rouse Tamer Refaat Yirong Zhu Jigisha P Thakkar Source Type: research
A phase 2, open-label study of ibrutinib plus rituximab in Japanese patients with Waldenstrom's macroglobulinemia
This study evaluated the efficacy and safety of ibrutinib-rituximab in Japanese patients with WM. Patients received ibrutinib 420 mg orally once daily plus weekly rituximab 375 mg/m2 IV (8 infusions total). The primary end point was major response rate (MRR; PR or better) by Independent Review Committee assessment. Secondary endpoints were progression-free survival (PFS), safety, pharmacokinetics, and biomarkers. Primary analysis was conducted in 16 patients [baseline, treatment naïve: 8 (50.0%); relapsed/refractory WM: 8 (50.0%)] who received ibrutinib-rituximab, after all patients completed Week 57 or end of treatment. ...
Source: International Journal of Hematology - April 10, 2024 Category: Hematology Authors: Koji Izutsu Hisashi Kato Naohiro Sekiguchi Tomoaki Fujisaki Toshiro Kawakita Naoshi Obara Kosei Matsue Mitsutaka Nishimoto Tomoyoshi Hatayama Mitsuo Inagaki Ei Fujikawa Source Type: research
A phase 2, open-label study of ibrutinib plus rituximab in Japanese patients with Waldenstrom's macroglobulinemia
This study evaluated the efficacy and safety of ibrutinib-rituximab in Japanese patients with WM. Patients received ibrutinib 420 mg orally once daily plus weekly rituximab 375 mg/m2 IV (8 infusions total). The primary end point was major response rate (MRR; PR or better) by Independent Review Committee assessment. Secondary endpoints were progression-free survival (PFS), safety, pharmacokinetics, and biomarkers. Primary analysis was conducted in 16 patients [baseline, treatment naïve: 8 (50.0%); relapsed/refractory WM: 8 (50.0%)] who received ibrutinib-rituximab, after all patients completed Week 57 or end of treatment. ...
Source: International Journal of Hematology - April 10, 2024 Category: Hematology Authors: Koji Izutsu Hisashi Kato Naohiro Sekiguchi Tomoaki Fujisaki Toshiro Kawakita Naoshi Obara Kosei Matsue Mitsutaka Nishimoto Tomoyoshi Hatayama Mitsuo Inagaki Ei Fujikawa Source Type: research
Real ‐world patient characteristics, treatment patterns, and treatment outcomes of patients with diffuse large B‐cell lymphoma by line of therapy
ConclusionsIn this real-world analysis, 25.2% of patients experienced R/R-DLBCL after 1L with poor outcomes. Given the findings of this study, there is a high unmet need for novel, safe, and effective treatment options for patients with R/R DLBCL. (Source: Cancer Medicine)
Source: Cancer Medicine - April 10, 2024 Category: Cancer & Oncology Authors: Helmneh M. Sineshaw,
Christina M. Zettler,
Jennifer Prescott,
Mahek Garg,
Samhita Chakraborty,
Eric M. Sarpong,
Claire Bai,
Andrew J. Belli,
Laura L. Fernandes,
Ching ‐Kun Wang Tags: RESEARCH ARTICLE Source Type: research
Systemic and Bilateral Severe Ocular Toxoplasmosis Resembling Autoimmune Phenomena: A Case Report
CONCLUSION AND IMPORTANCE: This case underscores the importance of ruling out an infectious etiology in all cases of uveitis. Additionally, it alerts clinicians to the possibility that elevated positive autoantibodies may result from a severe inflammatory reaction caused by pathogens rather than an autoimmune or autoinflammatory disease, particularly in instances of poor treatment response or atypical clinical presentation.PMID:38592492 | DOI:10.1080/09273948.2024.2336605 (Source: Ocular Immunology and Inflammation)
Source: Ocular Immunology and Inflammation - April 9, 2024 Category: Allergy & Immunology Authors: Sofia Romero-Santos Daniela Parra-Tanoux Carlos Cifuentes-Gonz ález Juliana Mu ñoz-Ortiz Germ án Mejía-Salgado Alejandra de-la-Torre Source Type: research
Clinical and biochemical evaluation of rituximab as add on therapy in neuromyelitis optica spectrum disorders
. (Source: International Journal of Neuroscience)
Source: International Journal of Neuroscience - April 8, 2024 Category: Neuroscience Authors: Chawen DingLei ZhengMingjian XiongDongping ZhangZhongmei ChenLinge WangZhihua LuoHong Qiaoa Department of Neurology, ChongGang General Hospital, Chongqing, Chinab Department of Ophthalmology, ChongGang General Hospital, Chongqing, China Source Type: research
Immunoglobulin G4-related disease and B-cell malignancy due to an IKZF1 gain-of-function variant
CONCLUSION: Heterozygosity for gain-of-function IKZF1 variants underlies autoimmunity/inflammatory diseases, IgG4-RD and B-cell malignancies, the onset of which may occur in adulthood. Clinical and immunological data are similar to those for patients with unexplained IgG4-RD. Patients may therefore benefit from treatments inhibiting pathways displaying IKAROS-mediated overactivity.PMID:38579942 | DOI:10.1016/j.jaci.2024.03.018 (Source: Clinical Lymphoma and Myeloma)
Source: Clinical Lymphoma and Myeloma - April 5, 2024 Category: Cancer & Oncology Authors: Blanca Garc ía-Solís Mar ía Tapia-Torres Ana Garc ía-Soidán Elisa Hern ández-Brito Mar ía Teresa Martínez-Saavedra Jos é M Lorenzo Salazar Sonia Garc ía-Hernández Ana Van Den Rym Karan Mayani Mayani Jos é Vicente Govantes-Rodríguez Adrian Ger Source Type: research
Therapeutic management of fibrosis in systemic sclerosis patients - an analysis from the Swiss EUSTAR cohort
CONCLUSION: Overall, in Switzerland, a wide range of medications is prescribed for systemic sclerosis patients. This includes modern, targeted treatments for which randomised controlled clinical trial have been recently reported.PMID:38579324 | DOI:10.57187/s.3630 (Source: Swiss Medical Weekly)
Source: Swiss Medical Weekly - April 5, 2024 Category: General Medicine Authors: Kevin Windirsch Suzana Jordan Mike Oliver Becker Cosimo Bruni Rucsandra Dobrota Muriel Elhai Ion-Alexandru Garaiman Carmen-Marina Mihai Michele Iudici Paul Hasler Camillo Ribi Britta Maurer Armando Gabrielli Anna-Maria Hoffmann-Vold Oliver Distler Source Type: research
Immunoglobulin G4-related disease and B-cell malignancy due to an IKZF1 gain-of-function variant
CONCLUSION: Heterozygosity for gain-of-function IKZF1 variants underlies autoimmunity/inflammatory diseases, IgG4-RD and B-cell malignancies, the onset of which may occur in adulthood. Clinical and immunological data are similar to those for patients with unexplained IgG4-RD. Patients may therefore benefit from treatments inhibiting pathways displaying IKAROS-mediated overactivity.PMID:38579942 | DOI:10.1016/j.jaci.2024.03.018 (Source: Clinical Lymphoma and Myeloma)
Source: Clinical Lymphoma and Myeloma - April 5, 2024 Category: Cancer & Oncology Authors: Blanca Garc ía-Solís Mar ía Tapia-Torres Ana Garc ía-Soidán Elisa Hern ández-Brito Mar ía Teresa Martínez-Saavedra Jos é M Lorenzo Salazar Sonia Garc ía-Hernández Ana Van Den Rym Karan Mayani Mayani Jos é Vicente Govantes-Rodríguez Adrian Ger Source Type: research
